Literature DB >> 19416217

Relaxin reduces fibrosis in models of progressive and established hepatic fibrosis.

Robert G Bennett1, Dean G Heimann, Dean J Tuma.   

Abstract

The effect of relaxin administration before (prevention) or after (treatment) the establishment of hepatic fibrosis in a mouse model was examined. In the prevention study, relaxin reduced collagen and smooth muscle actin content and significantly reduced serum levels of the liver enzymes alanine aminotransferase and aspartate aminotransferase. In the treatment study, administration of relaxin for 1 week reduced collagen and smooth muscle actin but not liver enzyme levels. Relaxin administered for 2 weeks had no significant effect. In conclusion, the data suggest that relaxin treatment before fibrosis can reduce collagen and improve liver function but that there is little effect of short-term relaxin treatment after fibrosis is established.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416217      PMCID: PMC2716062          DOI: 10.1111/j.1749-6632.2008.03783.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Inhibition of markers of hepatic stellate cell activation by the hormone relaxin.

Authors:  Robert G Bennett; Kusum K Kharbanda; Dean J Tuma
Journal:  Biochem Pharmacol       Date:  2003-09-01       Impact factor: 5.858

2.  Relaxin receptors in hepatic stellate cells and cirrhotic liver.

Authors:  Robert G Bennett; Shana R Dalton; Katrina J Mahan; Martha J Gentry-Nielsen; Frederick G Hamel; Dean J Tuma
Journal:  Biochem Pharmacol       Date:  2006-12-10       Impact factor: 5.858

3.  Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo.

Authors:  E J Williams; R C Benyon; N Trim; R Hadwin; B H Grove; M J Arthur; E N Unemori; J P Iredale
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

  3 in total
  9 in total

Review 1.  Molecular Pathways: Targeting the Microenvironment of Liver Metastases.

Authors:  Simon Milette; Jason K Sicklick; Andrew M Lowy; Pnina Brodt
Journal:  Clin Cancer Res       Date:  2017-06-14       Impact factor: 12.531

2.  Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.

Authors:  Elena M Kaftanovskaya; Hooi Hooi Ng; Mariluz Soula; Bryan Rivas; Courtney Myhr; Brian A Ho; Briana A Cervantes; Thomas D Shupe; Mahesh Devarasetty; Xin Hu; Xin Xu; Samarjit Patnaik; Kenneth J Wilson; Elena Barnaeva; Marc Ferrer; Noel T Southall; Juan J Marugan; Colin E Bishop; Irina U Agoulnik; Alexander I Agoulnik
Journal:  FASEB J       Date:  2019-08-16       Impact factor: 5.191

3.  Relaxin decreases the severity of established hepatic fibrosis in mice.

Authors:  Robert G Bennett; Dean G Heimann; Sudhir Singh; Ronda L Simpson; Dean J Tuma
Journal:  Liver Int       Date:  2013-07-21       Impact factor: 5.828

Review 4.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

Review 5.  Relaxin and its role in the development and treatment of fibrosis.

Authors:  Robert G Bennett
Journal:  Transl Res       Date:  2009-04-22       Impact factor: 7.012

Review 6.  It's all about the spaces between cells: role of extracellular matrix in liver fibrosis.

Authors:  Amit Khurana; Nilofer Sayed; Prince Allawadhi; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2021-04

Review 7.  Novel Anti-fibrotic Therapies.

Authors:  Benita L McVicker; Robert G Bennett
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

8.  Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis.

Authors:  Robert G Bennett; Ronda L Simpson; Frederick G Hamel
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

Review 9.  Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.

Authors:  Javier Díez
Journal:  Am J Cardiovasc Drugs       Date:  2014-08       Impact factor: 3.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.